🔎 Trials Near Me

Beranda › Neuropati Sensorik dan Otonom Herediter › Tennessee

Uji klinis Neuropati Sensorik dan Otonom Herediter di Tennessee

6 studi untuk Neuropati Sensorik dan Otonom Herediter mencari peserta di lokasi di Tennessee.

Kota di Tennessee

Teks studi resmi (Bahasa Inggris)

Study of ACR-2316 in Specific Advanced Solid Tumors

  • Tennessee Oncology, Franklin
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT06667141

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

  • Tennessee Oncology, PLLC, Chattanooga
  • SCRI Oncology Partners, Nashville
  • Vanderbilt Medical Center, Nashville
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Jul 2026 · NCT04657068

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

  • The West Clinic, PLLC dba West Cancer Center, Germantown
  • Sarah Cannon Research Institute, Nashville
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 7 Jul 2026 · NCT05768139

Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

  • SCRI Oncology Partners, Nashville
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Jul 2026 · NCT07558733

A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

  • Sarah Cannon Cancer Center, Nashville
  • Vanderbilt-Ingram Cancer Center, Nashville
Menerima pesertaFase 1
Usia 18 ke atas · Wanita · Diperbarui 22 Apr 2026 · NCT05683418

Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors

  • Sarah Cannon Research Institute, Nashville
Menerima pesertaStudi observasional
Usia 1 hingga 100 · Semua jenis kelamin · Diperbarui 1 Apr 2026 · NCT05868629

Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.